From Hain Life Sciences, GenoType® MTBDRsl is a molecular genetic assay which allows the simultaneous detection of the M.tuberculosis complex and its Resistance to Fluoroquinolones and/or Aminoglycosides/Cyclic Peptides and/or Ethambutol from smear-positive pulmonary clinical specimens or cultivated samples.
In combination with the GenoType® MTBDRplus the assay allows the detection of XDR-TB-cases.
The GenoType® MTBDRsl is based on the DNA STRIP® technology and permits the simultaneous molecular genetic identification of
the M. tuberculosis complex
its resistance to fluoroquinolones like ofloxacin and moxifloxacin by the detection of the most common mutations in the gyrA gene
its resistance to the injectable antibiotics (viomycin, kanamycin, amikacin and capreomycin) by detection of the most common mutations in the rrs gene
its resistance to the first-line drug ethambutol, by detection of the most common mutations in the embB gene
from smear-positive pulmonary clinical specimens or cultivated samples.
Indications for the use of GenoType® MTBDRsl Diagnosing patients
with MDR-TB to receive information on further antibiotic resistances
after therapy failure and relapse
from countries with high usage of the respective drugs
in high burden MDR-/XDR-TB regions
Benefits and advantages of using GenoType® MTBDRsl
Detection of XDR-TB in patients previously diagnosed with an MDR-TB by testing with the GenoType® MTBDRplus.
Confirmation of DST results.
Minimizing extreme side effects through an appropriate therapy scheme.
Highly economic as expensive, ineffective drugs can be avoided.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.